Companies: 10,795·Total market cap: $144.5T
Ovid Therapeutics Inc.

Ovid Therapeutics Inc.

OVIDNASDAQHealthcare● Active
$2.36
$-0.04(-1.67%)
Market Cap$311247347
P/E Ratio
52W High$3.105
52W Low$0.272
Overview

Ovid Therapeutics Inc. (OVID) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

ovid · stock forecast · 14 analysts (3M) · FMP · updated Jun 9, 2026

Analyst Rating & Consensus

Based on 14 Wall Street analysts in the past 3 months

SellBuy

Buy

14 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
11
Hold
3
Sell
0
Strong Sell
0
Total: 14 · Buy rate: 78.6%

12-Month Price Target

High

$7.00

Consensus

$5.50

+133.1% upside

Low

$4.00

Median: $5.5 · Last Close: $2.36

The Ovid Therapeutics Inc. (OVID) analyst consensus is Buy, based on ratings from 14 Wall Street analysts over the past 3 months. The average 12-month OVID price target is $5.50, representing +133.1% upside from the current price of $2.36.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $6 (133.1%)

Consensus Target

$5.50

133.1% upside

High Target

$7

196.6%

Low Target

$4

69.5%

Current Price

$2.36

as of today

Based on analyst price targets, the OVID stock price prediction for the next 12 months ranges from $4 to $7. The consensus OVID price forecast of $5.50 implies 133.1% upside from the current price of $2.36.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-10$2.273.86%

1-day model range: $2.25–$2.28. Peak: $2.28 (-3.86%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$3+42.0%
2028$4+74.9%
2029$5+97.1%
2030$5+110.9%
2031+119.0%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

29%7%64%
4Buy
1Neutral
9Sell
RSI (14)47.4Neutral
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · OVID · Jun 9, 2026

Simple Moving Average (SMA)
MA 5$2.41SELL
MA 10$2.50SELL
MA 20$2.55SELL
MA 50$2.61SELL
MA 100$2.19BUY
MA 200$1.83BUY
Current $OVID · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$2.42SELL
EMA 10$2.47SELL
EMA 20$2.53SELL
EMA 50$2.49SELL
EMA 100$2.27BUY
EMA 200$1.90BUY
Current $OVID · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Wedbush2026-04-15
Maintains
OutperformOutperform
HC Wainwright & Co.2026-04-09
Maintains
BuyBuy
BTIG2026-03-26
Maintains
BuyBuy
Wedbush2026-03-20
Maintains
OutperformOutperform
HC Wainwright & Co.2025-12-22
Maintains
BuyBuy
HC Wainwright & Co.2025-11-24
Maintains
BuyBuy
HC Wainwright & Co.2025-05-27
Maintains
BuyBuy
BTIG2025-03-24
Maintains
BuyBuy
HC Wainwright & Co.2025-03-24
Maintains
BuyBuy
Wedbush2025-03-12
Maintains
OutperformOutperform

Wall Street analysts have recently issued updated ratings on Ovid Therapeutics Inc. (OVID) stock. Of the recent 39 rating actions, 1 were upgrades and 3 were downgrades. 14 analysts currently cover OVID.

Analyst Recommendation Trends

Buy ratings321
Hold ratings00
Sell ratings00

OVID analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 3 to 2 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$0M

↓ 41.6% YoY

Revenue Next Year

$0M

↑ 39.5% YoY

EPS This Year

$-0.48

EPS Next Year

$-0.53

↑ 10.4% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast OVID EPS of $-0.48 for the current fiscal year, based on estimates from 8 analysts. The OVID revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The OVID stock forecast is supported by two independent data sources: analyst consensus ratings from 14 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus OVID price target is $5.50 (+133.1% upside), with an analyst consensus of Buy.

The OVID short-term stock prediction for tomorrow is $2.27 (-3.86%). The OVID stock price prediction for 2027 estimates an average of $3. The OVID stock prediction for 2030 projects a range of $5–$5.

Ovid Therapeutics Inc. trades on NASDAQ under the ticker OVID. The OVID stock outlook for 2027 is broadly positive, supported by a Buy consensus among 79% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

OVID forecast · 8 questions

According to 14 Wall Street analysts, the average 12-month OVID price target is $5.50, with a high forecast of $7.00 and a low of $4.00. The median price target is shown in the chart above when available. This implies +133.1% potential upside from the current price of $2.36.

OVID price targetWhat is OVID price targetOVID analyst price targetOVID 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.